34 results about "Cell Death Inhibition" patented technology

The present invention generally relates to devices and methods for the preservation of cells using drying, freezing, and other related techniques. In one set of embodiments, the invention allows for the preservation of cells in a dried state. In another set of embodiments, the invention allows for the preservation of cells within a glass or other non-viscous, non-frozen media. In some embodiments, the invention allows for the preservation of cells at temperatures below the freezing point of water, and in some cases at cryogenic temperatures, without inducing ice formation. The cells, in certain embodiments, may be preserved in the presence of intracellular and / or extracellular carbohydrates (which may be the same or different), for example, trehalose and sucrose. Carbohydrates may be transported intracellularly by any suitable technique, for example, using microinjection, or through non-microinjected methods such as through pore-forming proteins, electroporation, heat shock, etc. In certain instances, the glass transition temperature of the cells may be raised, e.g., by transporting a carbohydrate intracellularly. In some cases, the cells may be dried and / or stored, for example, in a substantially moisture-saturated environment or a desiccating environment. The cells may also be stored in a vacuum or a partial vacuum. The cells may be protected from oxygen, moisture, and / or light during storage. In certain cases, an inhibitor, such as a cell death inhibitor, a protease inhibitor, an apoptosis inhibitor, and / or an oxidative stress inhibitor may be used during preservation of the cells. The cells may be stored for any length of time, then recovered to a viable state, e.g., through rehydration, for further use.

Methods and apparatus are disclosed for treating congestive heart failure. The method includes relieving wall stress on a diseased heart by an amount to decrease a rate of myocardial cell loss. Further, the method includes pharmacologically encouraging a myocardial cell gain. Cell gain may be encouraged by cell replication, cell recruitment or inhibition of cell death. Further embodiments of the method include a passive cardiac constraint selected to reduce wall stress on the heart. An apparatus of the present invention includes a passive cardiac constraint and a pharmacological agent to encourage cell gain.

The present invention provides a peptide fragment or a series of peptide fragments having a cell death-inhibitory activity, having the amino acid sequence consisting of 103 amino acid residues at the C-terminal of selenoprotein P, or having said amino acid sequence with one or several amino acid residues therein being deleted, substituted or added, or having a partial sequence of either of the above amino acid sequences, a medicament for treatment comprising said peptide fragment or a series of peptide fragments, an antibody to said peptide fragment or a series of peptide fragments, and a method for screening a cell death-inhibitory activity using said peptide fragment or a series of peptide fragments. The preferable peptide fragment or a series of peptide fragments of the present invention has the amino acid sequences shown in SEQ ID NO: 1 and / or SEQ ID NO: 2 or has a partial sequence thereof.

The present invention provides preparations for efficaciously administering ginsenoside Rb1 or its salt useful as cytoprotective agents. More particularly, the present invention provides pharmaceutical compositions comprising ginsenoside Rb1 or its salt for inhibiting apoptosis or apoptosis-like cell death or pharmaceutical compositions comprising ginsenoside Rb1 or its salt for promoting the expression of a cell death-inhibitory gene product Bcl-xL. Further, the present invention provides preparations for intravenous administration comprising ginsenoside Rb1 or its salt. The above pharmaceutical compositions contain ginsenoside Rb1 or its salt at low extracellular concentrations in lesion, preferably at 1 ng / ml or less and still preferably at 1 to 100 fg / ml. These compositions promote the expression of the cell death-inhibitory gene product Bcl-xL and inhibit apoptosis or apoptosis-like cell death. The above preparations for intravenous administration are useful for therapy, prevention or treatment of many diseases, in particular, brain and nervous diseases.

This patent discloses the use of water-soluble substituted fullerenes as inhibitors of cell death. The substituted fullerenes comprise a fullerene core (Cn) and at least one of: (i) from 1 to 6 (>CX1X2) groups bonded to the fullerene core; (ii) from 1 to 18 —X3 groups bonded to the fullerene core; (iii) from 1 to 6 —X4— groups bonded to the fullerene core; or (iv) from 1 to 6 dendrons bonded to the fullerene core.

As prophylactic and / or therapeutic agents for cardiovascular diseases, bone or joint diseases, infectious diseases, inflammatory diseases, kidney diseases, etc. having safe and excellent effects of cell death inhibition, MIF binding, etc., there are provided compounds represented by formula: [wherein, R1 represents a halogen atom, etc., R2 represents a group represented by formula: (wherein, R3 represents hydrogen atom, an optionally substituted alkoxy, etc., R4 represents hydrogen atom, bromine atom, cyano, etc., R5 represents hydrogen atom, hydroxy, etc., R6 represents hydrogen atom, etc., R7 represents hydrogen atom, etc.) etc., and n represents an integer of 0 to 4] or salts thereof.

The invention provides hyaluronic acid oligosaccharides having a size selected from sizes of 4 to 60 saccharides, fractions containing the hyaluronic acid oligosaccharides and having particular physicochemical properties, and drugs containing the same. The hyaluronic acid oligosaccharides of the present invention are extremely useful, because they exert superior pharmaceutical effects as active ingredients of a heat shock protein expression promoter, cell death inhibitor, cell injury inhibitor and cell and tissue protecting agent (e.g., organ preservation agent, antiulcer agent, antihepatopathic agent, IL-10 production promoter or IL-8 production inhibitor) and exhibit high safety.

The present invention pertains to a pharmaceutical composition for the prevention or treatment of kidney disease, an inflammation inhibitor for the kidneys, an inflammatory cell death inhibitor for the kidneys, or a food for the prevention or improvement of kidney disease, that include D-serine or a derivative thereof. In addition, the present invention pertains to the use of D-serine or a derivative thereof, for the production of a pharmaceutical composition for the prevention or treatment of kidney disease.

The present invention relates to 3-(benzylamino)-4-(cyclohexylamino)-N-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 (Fer-1) analogues as cell death inhibitors by inhibition of ferroptosis and / or oxytosis for the treatment of stroke, myocardial infarction, diabetes, sepsis, the prevention of transplant rejection, neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, dementia with Lewy bodies and Friedreich's ataxia. The present invention further relates to pharmaceutical compositions of these compounds and discloses methods for making the compounds and the corresponding intermediate.

This patent discloses the use of water-soluble substituted fullerenes as inhibitors of cell death. The substituted fullerenes comprise a fullerene core (Cn) and at least one of: (i) from 1 to 6 (>CX1X2) groups bonded to the fullerene core; (ii) from 1 to 18 -X3 groups bonded to the fullerene core; (iii) from 1 to 6 -X4- groups bonded to the fullerene core; or (iv) from 1 to 6 dendrons bonded to the fullerene core.

An object of the present invention is to provide a pharmaceutical agent useful for treating and preventing neurological disease, having satisfactory solubility and oxidative stress-mediated cell death suppressive activity as well as capable of exhibiting excellent blood-brain barrier permeability. The present invention is directed to an acylaminoimidazole derivative represented by general formula (I) or a salt thereof, and a pharmaceutical and a therapeutic or preventive agent for neurological disease containing the same, as an active ingredient.

The present invention provides medicinal or pharmaceutical compositions and preparations for administration, which are useful as cytoprotective agents and a remedy for neurotrauma, comprising ginseng, its extract, ginseng components, metabolites thereof or salts thereof (for example, red ginseng powder or components thereof). More particularly, the present invention provides medicinal or pharmaceutical compositions for inhibiting apoptosis or apoptosis-like cell death, medicinal or pharmaceutical compositions for promoting the expression of a cell death-suppressing gene product BCl-xL, or preparations for oral or intravenous administration, comprising ginseng, its extracts, ginseng components, metabolites thereof or salts thereof preferably at low concentrations. These medicinal or pharmaceutical compositions and / or preparations for administration are characterized by containing, as the active ingredient(s), ginseng, its extracts, ginseng components, metabolites thereof or salts thereof at low concentrations. These drugs are useful for therapy, prevention or treatment of brain and nervous diseases, heart diseases, etc.

The present invention provides a stress resistant plant in which a cell death suppressing gene is introduced.